Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based Partner operating in the Health Diagnostics space. If you think a Partner is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
David Leathers
Special Partner of Abingworth
has over 25 years of life science venture investment experience. His directorships have included GeneMedicine, GenPharm International and Pharming. Before joining Abingworth in 1987 he worked at N M Rothschild& Sons, where he was involved in setting up and managing Biotechnology Investments Limited, whose early-stage venture portfolio included Amgen, Genzyme and Immunex. He qualified as a chartered accountant in 1966 and stayed in the profession until he joined the investment division of N M Rothschild & Sons in 1972, becoming a Director of Rothschild Asset Management in 1978. David assists with Abingworth’s investor relations.
Follow David Leathers:
About Abingworth, GenPharm International: Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs.
Kurt von Emster
Managing Partner of Abingworth
Follow Kurt von Emster:
About Abingworth: Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs.
Andrew Sinclair
Partner & Portfolio Manager of Abingworth
Andrew has more than 10 years experience as an analyst in the pharmaceutical and biotechnology sectors. He joined Abingworth in 2008 from HSBC Global Markets, where he was Senior Equity Analyst, Director, responsible for investment research in the mid-cap pharmaceutical sector. Previously, Andrew held biotechnology analyst positions at Credit Suisse and SG Cowen. He completed a PhD in Chemistry and Genetic Engineering at the BBSRC Institute of Plant Science, Norwich, and holds a BSc in Microbiology from King’s College London. Andrew qualified as a chartered accountant with KPMG. At Abingworth, he evaluates opportunities in public companies and is a fund manager for open market transactions.
Follow Andrew Sinclair:
About Abingworth: Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs.
James Abell
Partner and CFO of Abingworth
Jams has more than 14 years of venture capital experience and three years of operational experience in life science companies. His directorships have included Chroma Therapeutics, Clinical Designs and Syntaxin. He joined Abingworth as CFO in 1998, prior to which he was CFO of Prolifix from 1995 to 1998. He trained and qualified as a Chartered Accountant with KPMG. He holds a degree in Biology with Chemistry from the University of Southampton. James handles Abingworth’s finance and administration as well as investment matters, focusing on start-up companies.
Follow James Abell:
About Abingworth: Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs.
Genghis Lloyd-Harris
Partner of Abingworth
Follow Genghis Lloyd-Harris:
About Abingworth: Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs.
Sarah Shackelton
Partner, Marketing & Talent of Abingworth
Sarah markets Abingworth to pharmaceutical and biotechnology companies and expands our network with key industry executives and entrepreneurs. She also works with portfolio companies in building their boards and senior leadership teams. Sarah joined Abingworth in 2004 after managing senior level searches for healthcare and private equity clients, as well as venture capital firms and their portfolio companies, at global executive search firms, including Spencer Stuart. She worked with the pharmaceutical industry as a US trade negotiator and consultant, and with the European Bank for Reconstruction and Development,in a marketing capacity. She has a BA in International Relations from Pomona College, California, and an MA in Public Affairs from Princeton University
Follow Sarah Shackelton:
About Abingworth: Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs.
John Heard
Partner & General Counsel of Abingworth
John has completed more than 100 venture capital financings and exits for life science and technology start-up companies across Europe and in the US. He has also been actively involved in initiatives to improve the efficiency and effectiveness of venture capital deal structuring across Europe. John joined Abingworth in 2006 from Intel Capital, the venture capital investment arm of Intel Corporation, where he was European Legal Counsel. Prior to this, John was an Associate at the international financial law practise, Hughes Hubbard & Reed, based in Washington, DC, US, and subsequently in Paris, France. He is a member of the District of Columbia and Maryland State Bars, and has qualified as a UK Solicitor. At Abingworth, John is responsible for deal co-ordination and provides legal assistance to the life sciences and healthcare team in their investment programme.
Follow John Heard:
About Abingworth: Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs.
Mairi Johnson
Chief Partnerships Officer of Babylon
Mairi brings a wealth of knowledge gained from leading equities research analysis within investment banks. She uses her expertise in this field to drive focus on partnerships with international NGOs as Babylon scales its international reach into developing economies.
Follow Mairi Johnson:
About Babylon, Big Issue Invest: Babylon is a world leading, digital-first, value-based care company.
Jamie Freeman
Corporate Innovation Partner of Horizon Discovery
Follow Jamie Freeman:
About Horizon Discovery: Horizon is a gene editing company that designs & engineers genetically-modified cells, applying them to advance human health.
Jamie Freeman
Corporate Innovation Partner of Horizon Discovery
Follow Jamie Freeman:
About Horizon Discovery: Horizon is a gene editing company that designs & engineers genetically-modified cells, applying them to advance human health.
